Home › Recently closed › 2026-08524
Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comments
Comment period closed: closed 109 days ago (Jun 30, 2026).
Read on FederalRegister.gov · Official PDF · Docket on Regulations.gov · Add to calendar (.ics)
Summary (from the Federal Register abstract)
The Food and Drug Administration (FDA, the Agency, or we) is establishing a public docket to collect examples about how previous patient-focused drug development (PFDD) meetings have impacted stakeholders' drug development efforts. This includes impacts on community engagement, research priorities, advocacy strategies, medical product development programs, clinical practice, and other areas of interest.
- Document type
- Notice
- Federal Register document number
- 2026-08524
- Published
- May 1, 2026
- Action
- Notice; establishment of a public docket; request for information and comments.
- Docket
- FDA-2026-N-3947
- Comments posted on Regulations.gov (at last check)
- 69
- DATES section (from the document)
- Either electronic or written comments on the notice must be submitted by June 30, 2026
- Topics (auto-tagged)
- Other FDA topics
Source: Federal Register API, document 2026-08524. Federal Register text is a U.S. government work. Confirm dates in the official document; later documents may extend, reopen or correct them.